Rigel Pharmaceuticals Inc (NASDAQ:RIGL) — Market Cap & Net Worth
Market Cap & Net Worth: Rigel Pharmaceuticals Inc (RIGL)
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) has a market capitalization of $782.13 Million ($782.13 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10045 globally and #2718 in its home market, demonstrating a -6.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rigel Pharmaceuticals Inc's stock price $44.48 by its total outstanding shares 18679864 (18.68 Million). Also see RIGL total assets for a full breakdown of the balance sheet.
Rigel Pharmaceuticals Inc Market Cap History: 2015 to 2026
Rigel Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $566.00 Million to $830.88 Million (3.70% CAGR). Also see RIGL operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Rigel Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #286 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1049 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.04% | #167 of 263 |
Weight: Rigel Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rigel Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rigel Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Rigel Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.72x
Rigel Pharmaceuticals Inc's market cap is 2.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.18x
Rigel Pharmaceuticals Inc's market cap is 2.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $444.58 Million | $20.38 Million | -$69.22 Million | 21.81x | N/A |
| 2017 | $724.78 Million | $4.48 Million | -$77.99 Million | 161.64x | N/A |
| 2018 | $429.64 Million | $44.51 Million | -$70.48 Million | 9.65x | N/A |
| 2019 | $399.75 Million | $59.29 Million | -$66.55 Million | 6.74x | N/A |
| 2020 | $653.80 Million | $108.62 Million | -$29.74 Million | 6.02x | N/A |
| 2021 | $495.02 Million | $149.24 Million | -$17.91 Million | 3.32x | N/A |
| 2022 | $280.20 Million | $120.24 Million | -$58.57 Million | 2.33x | N/A |
| 2023 | $270.86 Million | $116.88 Million | -$25.09 Million | 2.32x | N/A |
| 2024 | $314.20 Million | $179.28 Million | $17.48 Million | 1.75x | 17.97x |
| 2025 | $800.06 Million | $294.28 Million | $367.02 Million | 2.72x | 2.18x |
Competitor Companies of RIGL by Market Capitalization
Companies near Rigel Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review RIGL goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Rigel Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Rigel Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Rigel Pharmaceuticals Inc's market cap moved from $566.00 Million to $ 830.88 Million, with a yearly change of 3.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $830.88 Million | +3.85% |
| 2025 | $800.06 Million | +154.64% |
| 2024 | $314.20 Million | +16.00% |
| 2023 | $270.86 Million | -3.33% |
| 2022 | $280.20 Million | -43.40% |
| 2021 | $495.02 Million | -24.29% |
| 2020 | $653.80 Million | +63.55% |
| 2019 | $399.75 Million | -6.96% |
| 2018 | $429.64 Million | -40.72% |
| 2017 | $724.78 Million | +63.03% |
| 2016 | $444.58 Million | -21.45% |
| 2015 | $566.00 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Rigel Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $782.13 Million USD |
| MoneyControl | $782.13 Million USD |
| MarketWatch | $782.13 Million USD |
| marketcap.company | $782.13 Million USD |
| Reuters | $782.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more